Similar results were observed in the other two BCR-ABL dependent CML cell lines KU812 and MEG-01, confirming that this drug has strong inhibitory effect in the BCR-ABL mediated signaling pathways (Figure 4B middle and right panel). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.